As part of the Guy Lafleur Programme supported by CHUM Foundation, four research teams at the CHUM Research Centre (CRCHUM) will receive $250,000 each for their precision oncology projects.

“These teams are the first to benefit from the grants awarded under the Agir plus vite que le cancer initiative. To date, thanks to our donors, we have raised more than $3.7 million,” says Pascale Bouchard, president and CEO of the Fondation du CHUM.

This funding was made possible by donations to the Guy Lafleur Fund and $500,000 from the Institut du cancer de Montréal.

“Precision oncology is about tailoring treatment. It means treating the right patient, at the right time, with the best possible therapeutic option,” says Réjean Lapointe, researcher at the CRCHUM (Cancer research theme) and scientific director of the Institut du cancer de Montréal.

Funded projects:

Dr. Isabelle Bourdeau—Cardiometabolic research theme
Co-investigators: Martine Tétreault, Éric Samarut and Dr. Domnique Trudel
In vivo functional genetics and biomarkers in pheochromocytomas and paragangliomas for precision medicine

Dr. Arielle Elkrief—Cancer research theme
Co-investigators: Dr. Normand Blais, Dr. Bertrand Routy, Dr. Vincent Quoc-Huy Trinh, Dr. Moishe Liberman, Dr. Domnique Trudel and Dr. Danh Tran-Thanh
Next-generation, living biobank using ctDNA and patient-derived cell lines to uncover novel biomarkers and investigational approaches in non-small cell lung cancer

Dr. Bertrand Routy—Cancer research theme
Co-investigators: Manuela Santos, Dr. Arielle Elkrief, Dr. Moishe Liberman, John Stagg and Dr. Normand Blais
Defining the importance of the mycobiome and its interrelationship with commensal bacteria in non-small cell lung cancer patients amenable to immunotherapy

Dr. Simon Turcotte—Cancer research theme
Co-investigators: John Stagg and Gerardo Ferbeyre
Targeting tumour antigens derived from chemotherapy-induced senecesence for the development of pancreatic cancer immunotherapy

Learn more about the Guy Lafleur Fund